Posts Tagged ‘targeted therapy’

Andarix Pharmaceuticals to Present at the Rare Disease Innovation Summit

Targeting Lung Cancer in Rare Disease Patient Populations SOMERVILLE, MA— June 19, 2018 — Andarix Pharmaceuticals, a clinical stage company aimed at developing targeted peptide therapies for hard to treat cancers, announced today that its Chief Executive Officer, Chris Adams, will present at the Rare Disease Innovation Summit set to take place in Cambridge ,…

Read More

Andarix Pharmaceuticals to Present at Regulatory Pathways Summit Conference

Personalized Medicine for Small Cell Lung Cancer SOMERVILLE, Mass.— January 29, 2018 — Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer announced that its Chief Executive Officer, Chris Adams, will present at the Innovative Regulatory Pathways Summit in Washington, DC. January 29-30, 2018. The conference will focus…

Read More

Andarix Pharmaceuticals Selected to Present at Lung Cancer Summit in Boston, MA

Targeted Tozaride Drug Therapy is effective for Small Cell Lung Cancer SOMERVILLE, Mass.— July 24, 2017 — Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer announced that its Chief Executive Officer, Chris Adams, will present at the Precision Lung Cancer Summit in Boston, Massachusetts July 25-26, 2017.…

Read More

Andarix Pharmaceuticals and Wuxi Fortune Pharmaceuticals Sign Drug Deal for China Market

Tozaride has demonstrated clinical effectiveness in treating lung cancer SOMERVILLE, Mass.— September 6, 2017— Andarix Pharmaceuticals Inc, a clinical stage company, and Wuxi Fortune Pharmaceuticals announced today the signing of an agreement to develop and commercialize a drug to treat lung and other cancers. As part of the agreement Wuxi Fortune will have certain rights…

Read More

Andarix Pharmaceuticals’ Targeted Therapy Reduced Tumor Size in Lung Cancer Study

Tozaride Demonstrates Significant Tumor Reduction in Clinical Study SOMERVILLE, Mass.—May 2, 2017— Andarix Pharmaceuticals, a clinical stage company, announced today the results of a phase1/2 clinical study in lung and neuroendocrine cancer patients. In an open label, single arm study, refractory lung cancer patients to standard of care therapy were identified by image analysis using…

Read More

Andarix and Tulane University Collaborate to Further Research on Mediators of Cancer Cell Signaling

Andarix’ R&D expands to include Notch Influencing Molecules   ANDARIX Pharmaceuticals, a clinical stage company developing targeted peptide therapy for cancers announced today that the Company has entered into an agreement with Tulane University, an institution at the forefront of modern medical innovation, to license the technology and intellectual property concerning Notch Influencing Molecules. The…

Read More